Imetelstat
Imetelstat is the first telomerase-blocking drug approved for any cancer; it frees many lower-risk MDS patients from transfusions after growth factors have failed.
IMerge (NEJM 2024): 8-week transfusion independence 40% vs 15% with placebo, with durable responses and reductions in mutant allele burden suggesting disease modification. Cytopenias are the main toxicity. Phase 3 in JAK-inhibitor-refractory myelofibrosis (IMpactMF) tests overall survival.
- Medicare
- Part B (clinician-administered)
Given by infusion or injection in a clinic or hospital outpatient department, so it is a Part B drug: Medicare pays 80% after the Part B deductible and the patient owes 20% coinsurance, uncapped in Original Medicare unless a Medigap policy applies. Every-four-week infusion for lower-risk MDS (approved June 2024).
- Commercial insurance
- covered with prior authorisation
Covered under the medical benefit with prior authorisation confirming diagnosis, biomarker status and line of therapy; site-of-care policies may steer infusions away from hospital outpatient departments. Transfusion-dependent lower-risk MDS after ESA failure.
- Assistance programmes
- PAN Foundation — Disease-specific co-pay and premium funds; open and closed funds change monthly.
- HealthWell Foundation
- CancerCare Co-Payment Assistance Foundation
- Patient Advocate Foundation Co-Pay Relief
- Leukemia & Lymphoma Society financial support
20% Part B coinsurance on a high-cost infusion adds up quickly: Medigap Plan G or N, Medicare Advantage maximum out-of-pocket, Medicaid dual eligibility, or a charity fund are the usual buffers.
Sources: Medicare.gov: Chemotherapy · Medicare.gov: Prescription drugs (outpatient, Part B). Not medical or financial advice; verify with your plan.
- Notes
- EU-licensed 2025 for lower-risk MDS anaemia; UK licence and NICE position not yet researched.
Sources: NICE search: imetelstat. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
Approvals
| Region | Year | Indication |
|---|---|---|
| US | 2024 | Low- to intermediate-1-risk MDS with transfusion-dependent anaemia after ESA failure |
| EU | 2025 | Lower-risk MDS transfusion-dependent anaemia |
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
IMerge validated telomerase as a drug target in cancer, decades after its discovery, and gave a second-line option for MDS patients whose anaemia no longer responds to erythropoietin or luspatercept. The hint of clonal reduction is what makes the drug interesting beyond transfusion counts. Cytopenias require close monitoring in the first cycles.
COMMANDS moved luspatercept from second line (after ESA failure, MEDALIST trial) to first line, offering transfusion-dependent lower-risk MDS patients a better chance of transfusion freedom from the start. It changed guidelines and labels in 2023. Erythropoietin remains a reasonable and cheaper option for patients without ring sideroblasts or with low transfusion burden.
Latest papers
topQuery for this drug: (TITLE:"Imetelstat" OR ABSTRACT:"Imetelstat" OR TITLE:"Rytelo" OR ABSTRACT:"Rytelo") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Imetelstat, not a curated reading list.